In AD, decreased fatty acid expression impedes elongases, resulting in altered skin lipids, interleukin-4 (IL-4) anomalies, and interleukin-13 (IL-13) abnormalities (Makowska et al. 2023). Here, IL13 is linked to Alzheimer disease.